EUVIMEDEUVIMED entdecken
Crossref

Are We Operating Smarter? Risk of Malignancy Across Bethesda Categories—A 10‐Year Institutional Experience

Shawn Joseph Thadathil iD, Karunya Gopal Rajagopal iD, Iona Leekha Mathew, Mihir Mohan, Sarah Mary Thampi, Sourabh Padmanabhan, Abhijith George iD

Head & Neck · 2026-07 · 48 (7) · 1737-1741

DOI: 10.1002/hed.70191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 10.02.2026. Verfasst von Shawn Joseph Thadathil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgical Oncology, VPS Lakeshore Hospital and Research Centre, Kochi, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Nodule. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The global incidence of thyroid cancer has risen over recent decades, largely attributed to increased detection of thyroid nodules. This trend has raised concerns regarding overdiagnosis and overtreatment. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) plays a pivotal role in preoperative risk stratification, yet clinical decision‐making remains challenging in indeterminate categories (Bethesda III–V), particularly in resource‐limited settings where molecular testing is unavailable.

Objective

To determine the risk of malignancy (ROM) for each TBSRTC category among patients who underwent thyroid surgery over a 10‐year period at a tertiary care center in India, and to compare these rates with the 2023 TBSRTC risk estimates.

Methods

This retrospective study analyzed fine‐needle aspiration cytology and histopathology data for all patients who underwent thyroid surgeries conducted between 2014 and 2024. ROM across TBSRTC categories was calculated and compared with established TBSRTC risk estimates.

Results

A 100% malignancy rate was observed in TBSRTC VI category, supporting the reliability of surgical decisions in this group. However, significantly higher malignancy rates were found in TBSRTC categories III (58.7%), IV (82.7%), and V (100%) compared to TBSRTC estimates (22%, 30%, and 74%, respectively). TBSRTC III nuclear had a significantly higher malignancy rate (70.0%) than TBSRTC III other (40.57%).

Conclusion

Institution specific malignancy data enhances the clinical utility of TBSRTC and improves patient counseling, particularly in settings where molecular diagnostics are not feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid NoduleHumansRetrospective StudiesMaleFemaleBiopsy, Fine-NeedleRisk AssessmentMiddle AgedAdultThyroidectomyIndia

Stichwörter der Autor:innen

BethesdaIII‐nuclearTBSRTCmalignancy riskmolecular testing

Autor:innen und Institutionen

  • Department of Head and Neck Surgical Oncology, VPS Lakeshore Hospital and Research Centre, Kochi, India.
  • Department of Pathology, VPS Lakeshore Hospital and Research Centre, Kochi, India.

ORCID-Profile: Shawn Joseph Thadathil, Karunya Gopal Rajagopal, Abhijith George

Zitieren

APA

Thadathil, S. J., Rajagopal, K. G., Mathew, I. L., Mohan, M., Thampi, S. M., Padmanabhan, S., & George, A. (2026). Are We Operating Smarter? Risk of Malignancy Across Bethesda Categories—A 10‐Year Institutional Experience. Head & Neck, 48(7), 1737-1741. https://doi.org/10.1002/hed.70191

Vancouver

Thadathil SJ, Rajagopal KG, Mathew IL, Mohan M, Thampi SM, Padmanabhan S, et al. Are We Operating Smarter? Risk of Malignancy Across Bethesda Categories—A 10‐Year Institutional Experience. Head & Neck. 2026;48(7):1737-1741. doi:10.1002/hed.70191

BibTeX
@article{Thadathil2026,
  author = {Thadathil, Shawn Joseph and Rajagopal, Karunya Gopal and Mathew, Iona Leekha and Mohan, Mihir and Thampi, Sarah Mary and Padmanabhan, Sourabh and George, Abhijith},
  title = {Are We Operating Smarter? Risk of Malignancy Across Bethesda Categories—A 10‐Year Institutional Experience},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {7},
  pages = {1737--1741},
  doi = {10.1002/hed.70191}
}
Kostenlos starten →